Assessment of the effect of perindopril orodispersible tablet at the dose of 0.150 mg/kg/day on muscular and myocardic functions in the early stage of Duchenne Muscular Dystrophy: a two-year, double-blind, randomised, placebo-controlled study

Not Applicable

Completed

• Conditions: Duchenne Muscular Dystrophy; Nervous System Diseases; Primary disorders of muscles

• Registration Number: ISRCTN49075167
• Lead Sponsor: Institut de Recherches Internationales Servier (France)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-02-16
• Study Completion: 2012-09-30
• Last Update Posted: 4 May 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Children, less than 7 years old with Duchenne Muscular Dystrophy and able to complete a 6-minute walk test

Exclusion Criteria

1. Long term treatment with corticoids
2. Treatment with ACE inhibitors or AT1 antagonists

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Six-minute walking distance, evaluated each 6 months

Secondary Outcome Measures

Name	Time	Method
<br> 1. Other muscular tests<br> 2. Echocardiography<br> 3. Respiratory function assessment<br><br> Evaluated at inclusion visit and end-of-study visit<br>